Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the <i> Mdr2 <sup>−/−</sup> </i> mouse model of sclerosing cholangitis via immunomodulatory effects-Reference-Cited by-同舟云学术

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2 ^−/− mouse model of sclerosing cholangitis via immunomodulatory effects

Published:2022-06-12 Issue:9 Volume:6 Page:2368-2378
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Fuchs Claudia D.¹,Dixon Emmanuel D.¹,Hendrikx Tim²³,Mlitz Veronika¹,Wahlström Annika⁴,Ståhlman Marcus⁴,Scharnagl Hubert⁵,Stojakovic Tatjana⁶,Binder Christoph J.²,Marschall Hanns‐Ulrich⁴,Trauner Michael¹

Affiliation:

1. Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III Medical University of Vienna Vienna Austria

2. Department of Laboratory Medicine Medical University of Vienna Vienna Austria

3. Department of Molecular Genetics Maastricht University Maastricht the Netherlands

4. Department of Molecular and Clinical Medicine Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

5. Clinical Institute of Medical and Chemical Laboratory Diagnostics Medical University of Graz Graz Austria

6. Clinical Institute of Medical and Chemical Laboratory Diagnostics University Hospital Graz Graz Austria

Funder

Austrian Science Fund

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1998

Reference32 articles.

1. Characterization of animal models for primary sclerosing cholangitis (PSC)

2. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

3. The cholangiopathies: Disorders of biliary epithelia

4. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

5. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abcb4-defect cholangitis mouse model with hydrophobic bile acid composition by in vivo liver-specific gene deletion;Journal of Lipid Research;2024-09

2. Cellular Interactions and Crosstalk Facilitating Biliary Fibrosis in Cholestasis;Cellular and Molecular Gastroenterology and Hepatology;2024

3. Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity;Liver International;2023-08-29

4. The roles of gut microbiota and its metabolites in diabetic nephropathy;Frontiers in Microbiology;2023-07-27

5. Preclinical Models and Promising Pharmacotherapeutic Strategies in Liver Fibrosis: An Update;Current Issues in Molecular Biology;2023-05-11